Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

Trial Profile

A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2018

At a glance

  • Drugs IRL 790 (Primary)
  • Indications Drug-induced dyskinesia; Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Integrative Research Laboratories
  • Most Recent Events

    • 18 Dec 2018 According to an IRLAB media release, top-line results are expected within 10 weeks after last patient have entered this study.
    • 18 Dec 2018 According to an IRLAB media release, as a result of actions taken by the company in the last few months, the recruitment pace in the study has tripled.To date, 66 patients suitable for treatment, fulfilling initial criteria, have been identified whereof a majority have been randomized to, or have finalized, treatment.The recruitment will continue throughout Dec 2018 and early 2019 to reach the planned 74 patients.
    • 18 Dec 2018 According to an IRLAB media release, the independent committee of experts i.e DSBM (Data Safety Monitoring Board) has reviewed safety data from the first set of patients that has completed this study.The DSMB concluded that there were no safety concerns and recommended continuation of this study according to the previously approved study protocol.The upcoming key milestone in the clinical program for IRL790 is the completion of this study recruitment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top